Company: CMND
Filing Date: 2025-11-26
Form Type: 6-K
Source: 0001213900-25-115110
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐

CONTENTS</div>

On November 26, 2025, Clearmind Medicine (the “Company”),
entered into a definitive securities purchase agreement (the “Securities Purchase Agreement”) with investors for the purchase
and sale of (i) 7,944,868 of the Company’s common shares, no par value (the “Common Shares”), and (ii) pre-funded warrants
(the “Pre-Funded Warrants”) to purchase up to 2,865,960 Common Shares, in a registered direct offering (the “Offering”)
at a purchase price of $0.12 per Common Share and $0.1199 per Pre-Funded Warrant.

The Pre-Funded Warrants will
be immediately exercisable at an exercise price of $0.0001 per Common Share, subject to adjustment as set forth therein, and will not
expire until exercised in full. The Pre-Funded Warrants may be exercised on a cashless basis.

A holder of the Pre-Funded
Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder (together with such holder’s
affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates or any other persons
whose beneficial ownership of Common Shares would be aggregated with the holder’s or any of the holder’s affiliates), would
beneficially own Common Shares in excess of 4.99% of the number of the Common Shares outstanding immediately after giving effect to such
exercise.

The Offering is expected to close on or about November 26, 2025, subject
to the